Neuronetics Inc
STIM4.660USD
+0.240+5.43%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
306.72MCap. mercado
PérdidaP/E TTM
Más Datos de Neuronetics Inc Compañía
Neuronetics, Inc. is a medical technology company focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment for people suffering from neurohealth conditions. In addition to selling the NeuroStar system and associated treatment sessions to customers, it operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or TMS) and Spravato (esketamine nasal spray) for the treatment of major depressive disorder (MDD) and other mental health disorders. NeuroStar Advanced Therapy is the TMS treatment for MDD in adults. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. It provides more than 1.68 million treatments to over 51,000 patients struggling with depression.
Información de la empresa
Símbolo de cotizaciónSTIM
Nombre de la empresaNeuronetics Inc
Fecha de salida a bolsaJun 28, 2018
Director ejecutivoMr. Keith J. Sullivan
Número de empleados716
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección3222 Phoenixville Pike
CiudadMALVERN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal19355
Teléfono18776007555
Sitio Webhttps://neurostar.com/neuronetics/
Símbolo de cotizaciónSTIM
Fecha de salida a bolsaJun 28, 2018
Director ejecutivoMr. Keith J. Sullivan
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.02M
+1.50%
Mr. Keith J. Sullivan
Mr. Keith J. Sullivan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.61M
--
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
578.24K
+6.69%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
327.90K
+10.07%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
178.03K
+20.27%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.02M
+1.50%
Mr. Keith J. Sullivan
Mr. Keith J. Sullivan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.61M
--
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
578.24K
+6.69%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
327.90K
+10.07%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
178.03K
+20.27%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Clinic revenue
18.66M
58.35%
Treatment sessions
9.76M
30.53%
NeuroStar Advanced Therapy System
3.01M
9.41%
Other
544.00K
1.70%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
31.48M
98.46%
International
492.00K
1.54%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Clinic revenue
18.66M
58.35%
Treatment sessions
9.76M
30.53%
NeuroStar Advanced Therapy System
3.01M
9.41%
Other
544.00K
1.70%
Estadísticas de accionistas
Actualizado: jue., 17 de jul
Actualizado: jue., 17 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Madryn Asset Management, LP
36.82%
The Vanguard Group, Inc.
3.50%
Cucuz (Sasha)
3.08%
Sullivan (Keith J)
2.44%
Balyasny Asset Management LP
2.15%
Other
52.00%
Accionistas
Accionistas
Proporción
Madryn Asset Management, LP
36.82%
The Vanguard Group, Inc.
3.50%
Cucuz (Sasha)
3.08%
Sullivan (Keith J)
2.44%
Balyasny Asset Management LP
2.15%
Other
52.00%
Tipos de accionistas
Accionistas
Proporción
Private Equity
36.82%
Hedge Fund
12.75%
Individual Investor
9.48%
Investment Advisor
7.53%
Investment Advisor/Hedge Fund
3.50%
Research Firm
1.84%
Pension Fund
0.09%
Bank and Trust
0.03%
Other
27.96%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
183
47.01M
71.42%
-4.23M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
2023Q2
222
21.10M
73.37%
-11.20M
2023Q1
226
22.33M
78.62%
-9.89M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Madryn Asset Management, LP
24.24M
36.82%
--
--
Mar 24, 2025
The Vanguard Group, Inc.
2.31M
3.5%
+1.02M
+79.97%
Mar 31, 2025
Cucuz (Sasha)
2.02M
3.08%
+30.00K
+1.50%
May 22, 2025
Sullivan (Keith J)
1.61M
2.44%
--
--
Mar 24, 2025
Balyasny Asset Management LP
1.42M
2.15%
-64.72K
-4.37%
Mar 31, 2025
Ikarian Capital LLC
1.10M
1.67%
+1.10M
--
Mar 31, 2025
Masters Capital Management, L.L.C.
1.00M
1.52%
-500.00K
-33.33%
Mar 31, 2025
Manatuck Hill Partners, LLC
920.00K
1.4%
+920.00K
--
Mar 31, 2025
Susquehanna International Group, LLP
761.91K
1.16%
+761.91K
--
Mar 31, 2025
Two Sigma Investments, LP
703.67K
1.07%
+703.67K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
AdvisorShares Psychedelics ETF
6.11%
Invesco NASDAQ Future Gen 200 ETF
0.4%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
Ver más
AdvisorShares Psychedelics ETF
Proporción6.11%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.4%
iShares Micro-Cap ETF
Proporción0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
